Nurix
The Director of Pharmaceutical Development at Nurix Therapeutics leads small‑molecule drug product development for oral and topical dosage forms, overseeing QbD‑based formulation, scale‑up, technology transfer, and late‑stage regulatory activities. The role requires cross‑functional collaboration, CDMO management, and mentorship of scientific staff, and is based on‑site in Brisbane, CA.
Headquarters
Brisbane, California, United States
Company Size
201-500 employees
Founded
2012
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing medicines that harness targeted protein degradation to treat cancer and autoimmune diseases. Using a proprietary platform that combines small-molecule degraders and Degradation Activating Compounds (DACs) to engage E3 ubiquitin ligases and the ubiquitin–proteasome system, Nurix aims to selectively remove disease-causing proteins. The company advances multiple discovery and development programs and collaborates with partners to translate its platform into novel therapies. Their mission, "Medicines to Outmatch Disease," guides efforts to create differentiated, targeted treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Nurix.
14% above the average for this role
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX)
1 month ago
Associate Scientist, Formulation Development
Eurofins
Associate Formulations Scientist
Eurofins
Sr. Scientist Formulation
Integrated Resources INC
Passionate About Product Development? Hiring Associate Formulation Scientist
Eurofins
Associate Formulations Scientist
Eurofins
Formulation Scientist
Integrated Resources INC